Immuneering Corporation Marketable Securities (Current)
Immuneering Corporation (IMRX) had Marketable Securities (Current) of $32.89 million as of 2022-12-31, per its 10-K filed 2023-03-06.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:MarketableSecuritiesCurrent · last filed 2023-03-06
- 2022-12-31: Marketable Securities, Current $32.89M.
- 2022-09-30: Marketable Securities, Current $40.78M.
- 2022-06-30: Marketable Securities, Current $40.16M.
- 2022-03-31: Marketable Securities, Current $62.57M.
| Period end | Marketable Securities, Current |
|---|---|
| 2022-12-31 | $32.89M 10-K · filed 2023-03-06 |
| 2022-09-30 | $40.78M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $40.16M 10-Q · filed 2022-08-10 |
| 2022-03-31 | $62.57M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $74.31M 10-K · filed 2023-03-06 |
| 2021-09-30 | $42.55M 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |